Since MASH is strongly associated with obesity and type 2 diabetes, the effects of insulin sensitizers, such as glucagon-like peptide-1 receptor agonists and pioglitazone, have been explored in MASH [3,4]. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.